

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Lindsay M. Morton, Sophia S. Wang, Susan S. Devesa, Patricia Hartge, Dennis D. Weisenburger, and Martha S. Linet

Because the causes of most lymphoid neoplasms remain unknown, comparison of incidence patterns by disease subtype may provide critical clues for future etiologic investigations. We therefore conducted a comprehensive assessment of 114 548 lymphoid neoplasms diagnosed during 1992-2001 in 12 Surveillance, Epidemiology, and End Results (SEER) registries according to the internationally recognized World Health Organization (WHO) lymphoma classification introduced in 2001. Cases coded in International Classification of Diseases for Oncology, Second Edition (ICD-O-2), were converted to ICD-O-3 for WHO subtype assignment.

Age-specific and age-adjusted rates were compared by sex and race (white, black, Asian). Age-adjusted trends in incidence were estimated by sex and race using weighted least squares log-linear regression. Diverse incidence patterns and trends were observed by lymphoid neoplasm subtype and population. In the elderly (75 years or older), rates of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma increased 1.4% and 1.8% per year, respectively, whereas rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year. Although whites bear the highest incidence burden for

most lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predominance was observed for plasma cell and T-cell neoplasms. Asians have considerably lower rates than whites and blacks for CLL/SLL and Hodgkin lymphoma. We conclude that the striking differences in incidence patterns by histologic subtype strongly suggest that there is etiologic heterogeneity among lymphoid neoplasms and support the pursuit of epidemiologic analysis by subtype. (Blood. 2006;107:265-276)

© 2006 by The American Society of Hematology

Introduction

Neoplasms originating in lymphoid tissue comprise a diverse yet closely related group of neoplasms, including non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma, and acute and chronic lymphocytic leukemia. Together, lymphoid neoplasms will yield approximately 93 420 incident cases and 38 000 deaths in the United States during 2005.¹ The etiology of lymphoid neoplasms remains largely unknown, although risk factors include certain infections as well as treatments and diseases that cause severe immunosuppression.²⁻⁹

Beginning prior to 1950, an epidemic of NHL but not other hematopoietic neoplasms has been well documented in many populations,^{10,11} with an estimated 50% increase in United States age-adjusted incidence from 1970 to 1990¹¹⁻¹⁴ (Figure 1). Changes in diagnostic practice over time and the emergence of the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) pandemic in the early 1980s contributed to the rise in NHL but are not sufficient to explain entirely these dramatic increases.^{12,15-19} Recent reports suggest that the steep rise in incidence may have slowed in the late 1990s,^{15,20-22} as shown in Figure 1. Interpretation of NHL rates as a single disease entity requires caution, however, because the rates reflect a combination of diagnostic and etiologic factors that may differ by disease subtype.

Categorizing the various lymphoid neoplasms has proven to be enormously challenging and has resulted in the evolution of numerous classification schemes over the past 50 years.²³⁻²⁷ In

2001, the World Health Organization (WHO) introduced a new system for classifying hematopoietic neoplasms. Whereas previous classifications relied predominantly on morphology, the new WHO classification incorporates morphology, immunophenotype, cytogenetic and molecular features, clinical behavior, and some known aspects of etiology and pathogenesis into the definition of each disease subtype.²⁸ Additionally, the WHO classification highlights the interrelatedness of the various lymphoid neoplasms based on the cell of origin.

In light of the changing classifications, few comprehensive descriptive analyses of the patterns and time trends of lymphoid neoplasm subtypes have been conducted. Some of us previously evaluated the incidence patterns of lymphoid neoplasms diagnosed during 1978-1995 in 9 United States population-based cancer registries²⁹ using the earlier Working Formulation classification.²⁶ Even with this less satisfactory classification scheme, the feasibility and importance of distinguishing among lymphoid neoplasms has been demonstrated. Other reports on incidence patterns of individual subtypes during the last 15 years also suggest that patterns vary among the lymphoid neoplasms.^{11-13,15,17,30-39}

To date, no systematic descriptive analysis has considered incidence patterns for the entirety of lymphoid neoplasm subtypes as defined by the WHO classification.²⁸ Because the causes of most lymphoid neoplasms remain largely unknown, comparison of incidence rates and patterns for specific subtypes may provide

From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Rockville, MD; and Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha.

Submitted June 24, 2005; accepted August 26, 2005. Prepublished online as *Blood* First Edition Paper, September 8, 2005; DOI 10.1182/blood-2005-06-2508.

Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.

Reprints: Lindsay M. Morton, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS/7055, Rockville, MD 20852; e-mail: mortonli@mail.nih.gov.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2006 by The American Society of Hematology




Figure 1. Trends in incidence of hematopoietic neoplasms by broad subtype category, 9 SEER registries, 1978-1979 to 2000-2001. *All incidence rates are age adjusted to the 2000 United States population and presented for 12 fixed 2-year time periods (1978-1979 to 2000-2001). †Lymphoid neoplasms excepting Hodgkin lymphoma and plasma-cell neoplasms. ‡Predominantly myeloid leukemia. §Predominantly multiple myeloma.

critical clues for future etiologic investigations. Recent adoption of the International Classification of Diseases for Oncology, Third Edition (ICD-O-3), by United States cancer registries and the ability to convert cases coded in ICD-O-2 to ICD-O-3⁴⁰ make it feasible for the first time to assess incidence patterns and trends for lymphoid neoplasms according to the internationally recognized World Health Organization (WHO) classification introduced in 2001. We therefore conducted an analysis of the patterns and time trends of 114 548 incident lymphoid neoplasms diagnosed during 1992-2001 in 12 United States population-based cancer registries using the new WHO classification.²⁸

Patients, materials, and methods

Incidence data were obtained from the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program.⁴¹ SEER data collection began in the early 1970s with population-based registries in 5 states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and 4 metropolitan areas (Detroit, MI; San Francisco/Oakland, CA; Seattle/Puget Sound, WA; and Atlanta, GA).¹⁴ SEER expanded in 1992 to include two additional metropolitan areas (Los Angeles County and San Jose/Monterey, CA) and the Alaska Native Tumor Registry.⁴² Together these 12 regions account for approximately 14% of the United States population.⁴³ Our analysis considers the incidence of all lymphoid neoplasms diagnosed during the 10-year study period beginning January 1, 1992, when data first were combined from all 12 registries, and ending December 31, 2001, the most recent time for which complete data are available; this analysis utilizes data from the November 2003 SEER data submission, released in April 2004.⁴²

For each newly identified lymphoid neoplasm case, SEER registries report patient demographic data, including age, race, ethnicity, and sex, and information on the tumor histologic type, primary site, behavior (benign or malignant), and immunophenotype (B cell, T/natural killer [NK] cell, or unknown). Data regarding B-cell versus T/NK-cell lineage have been recorded in SEER registries since the 1970s, although prior to 1990 the proportion of cases with immunophenotype data are small.²⁹ Cases with known race were grouped into whites, blacks, Asians or Pacific Islanders

(hereafter referred to as "Asians"), and American Indians or Alaska Natives; a total of 650 (1.0%) men and 519 (1.0%) women were excluded from race-specific analyses because they were recorded as unknown race. Analysis of the incidence of lymphoid neoplasms by Hispanic ethnicity is beyond the scope of this paper because ethnicity is not recorded reliably in all 12 of the registries used in this analysis.⁴¹ Data on histologic type and primary site were coded according to ICD-O-2,⁴⁴ for cases diagnosed during 1992-2000, or according to ICD-O-3⁴⁵ for cases diagnosed in 2001. SEER uses a conversion algorithm to translate cases coded using ICD-O-2 to ICD-O-3.⁴⁰

Lymphoid neoplasm classification

The history of classifying lymphoid neoplasms since the 1940s has been reviewed previously.^{23,25,27} Briefly, beginning in 1982, the United States National Cancer Institute proposed the Working Formulation, which emphasized groupings according to morphology and clinical prognosis, to translate among the various lymphoma classifications in use at the time (eg, Rappaport, Lukes-Collins, Kiel).²⁶ Prior to 1994, the Working Formulation was adopted in the United States, whereas an updated Kiel classification was used in Europe.⁴⁶ Based on advances in knowledge, the Working Formulation and Kiel classifications were replaced in 1994 with the Revised European-American Lymphoma (REAL) classification, which incorporated morphologic, immunophenotypic, genotypic, and clinical features into disease subtype definitions.²⁴ With the advent of the REAL classification, several changes were made to the classification of lymphomas used by SEER registries, including the addition of ICD-O-2 codes for marginal zone lymphoma (ICD-O-2 codes 9710, 9711, 9715) and the addition of the term "mantle cell" (in contrast to "mantle zone") lymphoma.⁴⁰ Since the 1970s the leukemias have been classified predominantly using the French-American-British (FAB) classification.^{47,48} Updated terminology from the FAB classification also has been incorporated into ICD-O periodically.^{40,47-49}

The WHO classification introduced in 2001 builds on the REAL and FAB classifications and is the current gold standard for classifying all hematopoietic neoplasms.²⁸ The WHO system distinguishes hematologic malignancies according to cell lineage: lymphoid, myeloid, histiocytic/dendritic, and mast cells. Within the lymphoid neoplasms, morphologic and immunologic characteristics distinguish Hodgkin lymphomas from the NHLs. Stage of differentiation and additional morphologic, phenotypic, genotypic, and clinical features distinguish among the NHL subtypes. Lymphomas and corresponding lymphoid leukemias are presently considered different phases (solid versus circulating, respectively) of the same disease entity. By incorporating WHO terminology into the classification of hematologic malignancies used by SEER registries, ICD-O-3 provides a valuable link between WHO subtypes and historical data in the United States.

The ICD-O-3 codes and immunophenotype data reported by 12 SEER registries were used to categorize cases according to the WHO classification.²⁸ The ICD-O-3 codes included in each WHO disease entity were reviewed by an expert hematopathologist (D.D.W.). The classification of WHO disease entities and ICD-O-3 codes considered in the current analysis are presented in Table 1. All data refer to the incidence of neoplasms with malignant behavior.

Statistical analysis

Incidence rates, computed by aggregating county resident population estimates from the United States Census Bureau, were directly age adjusted to the 2000 United States standard population and expressed per 100 000 person-years.⁴¹ Age-specific rates were computed for 8 groups (less than 15, 15 to 24, 25 to 34, 35 to 44, 45 to 54, 55 to 64, 65 to 74, and 75 or more years); the age-specific rates for these 8 groups were age adjusted by 5-year groups. Certain analyses were conducted separately for the elderly (persons aged 75 years or older) and for persons less than 25 years of age, as has been done in some other investigations assessing combined groupings of leukemias and lymphomas in children and young persons (eg, Roman et al).⁵⁰ Rates, standard errors, and 95% confidence intervals (95% CIs) were computed using SEER*Stat software, version 5.2.2.⁵¹ Incidence rates were compared by sex for each of 3 racial groups (whites, blacks, Asians) and by

race for each sex using incidence rate ratios (IRRs) and an approximate 95% CI for the IRR.⁵² The small number of cases precluded analysis of the incidence of lymphoid neoplasms for American Indians/Alaska Natives.

Temporal trends were quantified by estimates of the annual percent change (APC) computed using weighted least squares log-linear regression.⁵¹ Briefly, this method fits a single, straight-line model that regresses the calendar year against the natural logarithm of the annual rate, weighted by the reciprocal of the variance of the natural logarithm of the incidence rate. The slope of this line and the standard error are used to compute a point estimate and 95% CI for the APC. The incidence rate was determined to have changed over time if the APC differed significantly from zero based on a 2-sided *P* value less than .05.

Figures are presented with the incidence rate per 100 000 person-years on the y-axis using a log scale and age or year of diagnosis on the x-axis. Temporal trends are portrayed visually using fixed time periods (Figure 1: 1978-1979 to 2000-2001; Figure 4: 1992-1995, 1996-1998, 1999-2001). Age-specific incidence is portrayed visually using 8 10-year age groups, from less than 15 to 75 or more years of age. A uniform scaling ratio (1 log cycle on the y-axis has the same length as 40 years on the x-axis, with a 10-degree slope representing an annual change of 1%) was used to facilitate comparison among figures for different disease subtypes.⁵³

Results

A total of 136 985 cases of hematopoietic neoplasms were diagnosed during 1992-2001 among residents of 12 SEER registries, of which 114 548 (84%) were lymphoid neoplasms (Table 1). Of the remaining 22 437 hematopoietic neoplasms, 88% were myeloid leukemias. In the present analysis, we focused on the incidence of lymphoid neoplasms. Mature B-cell neoplasms accounted for approximately three quarters of all lymphoid neoplasms, Hodgkin lymphoma accounted for 8%, mature T/NK-cell neoplasms and lymphoblastic leukemia/lymphoma each accounted for 5%, and lymphoid neoplasms of unknown type accounted for 7%. Mature B-cell neoplasms comprised diffuse large B-cell lymphoma (DLBCL) (28%), plasma cell neoplasms (predominantly multiple myeloma) (22%), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (20%), follicular lymphoma (13%), and various other known or unknown types (16%).

Incidence rate ratios by sex

Males had higher rates than females for most lymphoid neoplasm subtypes. The male-to-female (M/F) IRR was 1.5 to 1.6 for all lymphoid neoplasms combined and significantly greater than unity for virtually all subtypes (Tables 2-3). Among B-cell neoplasms, male predominance was most pronounced for Burkitt lymphoma/leukemia and hairy cell leukemia, with the M/F IRR among whites exceeding 3. The M/F IRRs ranged between 2 and 3 for mantle cell lymphoma, plasmacytoma, and Waldenström macroglobulinemia. Rates differed little by sex for marginal zone and follicular lymphomas. Among T-cell neoplasms, the M/F IRR among whites was 1.8 to 2.0 for the major subtypes. Although no sex difference was observed for nodular sclerositis Hodgkin lymphoma, a 2-fold male predominance in whites was seen for mixed cellularity/lymphocyte depleted Hodgkin lymphoma and a 3-fold male predominance in whites was seen for nodular lymphocyte predominant Hodgkin lymphoma. The M/F IRRs among blacks and Asians generally were similar to those among whites for most subtypes, with only a few notable exceptions. The M/F IRRs among blacks were lower for mycosis fungoides/Sézary syndrome and nodular lymphocyte predominant Hodgkin lymphoma and higher for follicular lymphoma, angioimmunoblastic lymphoma, and mixed

cellularity/lymphocyte depleted Hodgkin lymphoma compared with whites. The M/F IRRs among Asians were lower for Burkitt lymphoma/leukemia, anaplastic large-cell lymphoma, and nodular lymphocyte predominant Hodgkin lymphoma and higher for lymphoplasmacytic lymphoma.

Incidence rate ratios by race

Total lymphoid neoplasm rates were 10% higher for whites than for blacks (Tables 2-3). Among B-cell neoplasms, white predominance was most pronounced for hairy cell leukemia, follicular lymphoma, mantle cell lymphoma, and Waldenström macroglobulinemia (white-to-black [W/B] IRR among males, 2 to 3). In contrast, black predominance was observed for plasma cell neoplasms (W/B IRR among males, 0.5) and for mycosis fungoides/Sézary syndrome and peripheral T-cell lymphoma (W/B IRR among males, 0.7 to 0.8). Among B- and T-cell neoplasms, the W/B IRRs among females generally were similar to those among males, except for a higher W/B IRR for follicular lymphoma and a lower W/B IRR for mycosis fungoides/Sézary syndrome among females compared with males. Among the Hodgkin lymphomas, regardless of sex, the W/B IRRs ranged from 1.0 to 1.4 for the classical Hodgkin lymphomas, whereas a black predominance was observed for nodular lymphocyte predominant Hodgkin lymphoma (W/B IRR, 0.6 and 0.2 for males and females, respectively).

Total lymphoid neoplasm rates were 70% higher for whites than for Asians (Tables 2-3). Among B-cell neoplasms, the white-to-Asian (W/A) IRR among males was more than 3 for CLL/SLL and hairy cell leukemia and ranged from 2 to 3 for follicular and mantle cell lymphomas. Notably, rates differed little between whites and Asians for DLBCL, marginal zone lymphoma, Burkitt lymphoma/leukemia, and lymphoplasmacytic lymphoma. Among B-cell neoplasms, the W/A IRRs among females were similar to those among males, except for a higher W/A IRR for lymphoplasmacytic lymphoma for females compared with males. Among T-cell neoplasms, regardless of sex, the W/A IRR for mycosis fungoides/Sézary syndrome was 1.4, whereas the W/A IRR approached unity for peripheral T-cell lymphoma. Among classic Hodgkin lymphomas, regardless of sex, the W/A IRRs ranged from 2.1 to 3.4. In contrast, the W/A IRRs for nodular lymphocyte predominant Hodgkin lymphoma were 5.0 and 1.5 among males and females, respectively.

Age-specific incidence

The incidence of total lymphoid neoplasms increased monotonically with age in all race and sex subgroups (Figure 2A). Steep increases in incidence with age were observed for most subtypes, with several notable exceptions. Burkitt lymphoma/leukemia and mixed cellularity/lymphocyte depleted Hodgkin lymphoma rates increased more gradually with age (Figure 2G,N). B-cell and T-cell lymphoblastic lymphoma/leukemia were diagnosed predominantly in children (Figure 2K,L). Nodular sclerositis and nodular lymphocyte predominant Hodgkin lymphomas were diagnosed predominantly in persons aged 15 to 34 years and 15 to 64 years, respectively (Figure 2M,O).

We observed similar patterns in the race and sex subgroups for most but not all lymphoid neoplasm subtypes. Substantially higher rates were observed among white and black men aged 25 to 54 years for DLBCL, Burkitt lymphoma/leukemia, mixed cellularity/lymphocyte depleted Hodgkin lymphoma, and unknown type lymphoid neoplasms (Figure 2B,G,N,P).

Table 1. Incidence of hematopoietic neoplasms by subtype and ICD-O-3 codes, 12 SEER registries, 1992-2001

Hematopoietic neoplasm subtype	ICD-O-3 codes*†	No.	Rate‡
Lymphoid neoplasms, total	—	114 548	33.65
B-cell lymphoid neoplasms, total	9590-9591 (B), 9596(B), 9670-9671, 9673, 9675(B), 9678-9680, 9684, 9687, 9689-9691, 9695, 9698-9699, 9727(B), 9728, 9731-9734, 9761, 9764, 9820(B), 9823, 9826, 9832(B), 9833, 9835(B), 9836, 9940, 9970(B)	87 666	26.13
DLBCL	9675(B), 9678-9680, 9684	24 246	7.14
Marginal zone lymphoma	9689, 9699	3247	0.97
Follicular lymphoma	9690-9691, 9695, 9698	10 705	3.18
CLL/SLL	9670, 9823	16 984	5.17
Mantle cell lymphoma	9673	1691	0.51
Burkitt lymphoma/leukemia	9687, 9826	1102	0.30
Plasma cell neoplasms	9731-9734	18 644	5.66
Multiple myeloma	9732	17 407	5.29
Plasma cell leukemia	9733	107	0.03
Plasmacytoma	9731, 9734	1130	0.34
Hairy cell leukemia	9940	1116	0.33
Lymphoplasmacytic lymphoma	9671	911	0.27
Waldenstrom macroglobulinemia	9761	1144	0.35
B-cell lymphoid neoplasms, NOS	9590-9591 (B), 9596(B), 9764, 9820(B), 9970(B)	4872	1.45
T/NK-cell lymphoid neoplasms, total	9590-9591 (T/NK), 9596(T/NK), 9675(T/NK), 9700-9702, 9705, 9708-9709, 9714, 9716-9719, 9727(T/NK), 9729, 9820(T/NK), 9827, 9831, 9832(T/NK), 9834, 9835(T/NK), 9837, 9948, 9970(T/NK)	6228	1.79
Mycosis fungoides/Sézary syndrome	9700-9701	1773	0.52
Peripheral T-cell lymphoma	9675(T/NK), 9702, 9705, 9708, 9714, 9716, 9827	2071	0.60
Angioimmunoblastic lymphoma	9705	176	0.05
Anaplastic large-cell lymphoma	9714	864	0.25
Peripheral T-cell lymphoma, NOS	9675(T/NK), 9702, 9708, 9716, 9827	1031	0.30
T/NK-cell lymphoid neoplasms, NOS	9590-9591 (T/NK), 9596(T/NK), 9709, 9717-9719, 9820(T/NK), 9831, 9948, 9970(T/NK)	1501	0.44
Lymphoblastic leukemia/lymphoma§	9727-9729, 9835-9837	6127	1.61
B-cell lymphoblastic leukemia/lymphoma	9727(B), 9728, 9835(B), 9836	2907	0.76
T-cell lymphoblastic leukemia/lymphoma	9727(T/NK), 9729, 9835(T/NK), 9837	852	0.22
Unknown type lymphoblastic leukemia/lymphoma	9727, 9835(unknown)	2368	0.63
Polymorphocytic leukemia	9832-9834	237	0.07
Hodgkin lymphoma	9650-9655, 9659, 9661-9665, 9667	10 042	2.67
Classical Hodgkin lymphoma	9650-9655, 9661-9665, 9667	9734	2.59
Nodular sclerosis	9663-9665, 9667	6270	1.63
Mixed cellularity/lymphocyte depleted	9652-9655	1906	0.53
Classical Hodgkin lymphoma, NOS	9650-9651, 9661-9662	1558	0.43
Nodular lymphocyte predominant Hodgkin lymphoma	9659	308	0.08
Unknown type lymphoid neoplasms	9590-9591 (unknown), 9596(unknown), 9675(unknown), 9820(unknown), 9970(unknown)	8135	2.40
Nonlymphoid hematopoietic neoplasms, total	—	22 437	6.63
Chronic myeloproliferative diseases	9950, 9960-9964, 9975		
Myelodysplastic syndromes	9980, 9982-9987, 9989		
Myeloid leukemias	9840, 9860-9861, 9863, 9866-9867, 9870-9876, 9891, 9895-9897, 9910, 9920, 9930-9931, 9945-9946	19 640	5.78
Acute myeloid leukemias	9840, 9861, 9866-9867, 9870-9874, 9891, 9895-9897, 9910, 9920, 9930-9931	13 358	3.93
Chronic myeloid leukemias	9863, 9875-9876, 9945-9946	5863	1.72
Myeloid leukemias, NOS	9860	419	0.13
Leukemias, NOS	9800-9801, 9805	2597	0.79
Mast cell neoplasms	9740-9742	65	0.02
Histiocytic and dendritic cell neoplasms	9750-9758	122	0.03
Other hematopoietic diseases	9760, 9762, 9765-9769	13	0.00
Hematopoietic neoplasms total	—	136 985	40.28

ICD-O-3 indicates International Classification of Diseases for Oncology, Third Edition; SEER, Surveillance, Epidemiology, and End Results; DLBCL, diffuse large B-cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; NOS, not otherwise specified; NK, natural killer (cell).

*Data on histologic type and primary site were coded to ICD-O-2 (44) for cases diagnosed between 1992 and 2000 or ICD-O-3 (45) for cases diagnosed in 2001. SEER used a conversion algorithm to translate cases coded using ICD-O-2 to ICD-O-3 (40).

†Codes followed by parentheses indicate that immunophenotyping data (B-cell, T/NK-cell, or unknown) were used to assign cases to that lymphoid neoplasm subtype.

‡All incidence rates are age adjusted to the 2000 United States population and expressed per 100 000 person-years.

§Also known as acute lymphoblastic leukemia (ALL).

||Chronic myeloproliferative diseases and myelodysplastic syndromes, now classified as malignant in ICD-O-3, were classified as uncertain behavior in ICD-O-2 and thus were not reportable to SEER until 2001. In 2001, 634 cases (1.77 cases per 100 000 persons) of chronic myeloproliferative diseases and 1024 cases (2.91 cases per 100 000 persons) of myelodysplastic syndromes were diagnosed. These disease entities were excluded from our analysis.

||Lymphoid versus myeloid origin not determined.

Table 2. Incidence of lymphoid neoplasms by subtype, race, and sex, 12 SEER registries, 1992-2001

Lymphoid neoplasm subtype	Men								Women							
	White		Black		Asian		AI/AN		White		Black		Asian		AI/AN	
	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*
Lymphoid neoplasms, total	53 875	44.01	5390	41.09	3688	25.38	244	16.25	42 561	27.97	4468	26.53	2932	16.76	221	12.45
B-cell lymphoid neoplasms, total	41 127	34.31	3893	31.94	2813	19.77	168	11.99	33 058	21.66	3345	20.75	2318	13.46	174	10.43
DLBCL	11 529	9.35	940	6.45	1010	7.09	43	3.10	9099	5.93	625	3.60	840	4.92	46	2.71
Marginal zone lymphoma	1153	0.97	96	0.82	167	1.19	5	0.30	1483	0.98	120	0.72	178	1.01	6	0.41
Follicular lymphoma	4738	3.85	244	1.87	233	1.59	15	1.04	4902	3.31	202	1.20	245	1.37	27	1.78
CLL/SLL	8796	7.72	646	5.86	251	1.77	16	1.19	6361	4.09	461	3.00	157	0.95	16	1.13
Mantle cell lymphoma	989	0.84	52	0.45	48	0.32	4	0.36	518	0.34	37	0.23	31	0.18	4	0.26
Burkitt lymphoma/leukemia	677	0.49	76	0.42	66	0.38	5	0.20	221	0.15	21	0.11	28	0.17	0	0.00
Plasma cell neoplasms	7739	6.72	1445	13.40	560	4.21	49	4.13	6601	4.28	1605	10.35	478	2.84	47	3.10
Multiple myeloma	7098	6.20	1367	12.74	520	3.93	43	3.76	6231	4.04	1529	9.89	458	2.73	46	3.01
Plasma cell leukemia	46	0.04	8	0.08	0	0.00	0	0.00	37	0.02	13	0.08	3	0.02	0	0.00
Plasmacytoma	595	0.49	70	0.58	40	0.29	6	0.37	333	0.22	63	0.38	17	0.10	1	0.10
Hairy cell leukemia	782	0.62	25	0.21	27	0.20	1	0.06	243	0.16	10	0.06	7	0.04	1	0.04
Lymphoplasmacytic lymphoma	407	0.35	37	0.29	39	0.30	0	0.00	350	0.23	45	0.27	16	0.10	1	0.03
Waldenström macroglobulinemia	629	0.56	31	0.25	42	0.32	2	0.18	388	0.25	15	0.10	22	0.14	0	0.00
B-cell lymphoid neoplasms, NOS	2236	1.84	213	1.51	224	1.65	12	0.99	1826	1.20	131	0.78	182	1.07	8	0.42
T/NK-cell lymphoid neoplasms, total	2950	2.33	405	2.71	327	2.14	31	2.06	1820	1.23	324	1.81	208	1.14	13	0.57
Mycosis fungoides/Sézary syndrome	781	0.64	123	0.88	66	0.46	6	0.35	525	0.36	129	0.73	45	0.25	4	0.15
Peripheral T-cell lymphoma	942	0.75	139	0.96	119	0.82	13	1.11	638	0.42	102	0.57	90	0.51	6	0.33
Angioimmunoblastic lymphoma	66	0.05	8	0.07	15	0.11	0	0.00	68	0.04	7	0.04	11	0.06	0	0.00
Anaplastic large-cell lymphoma	435	0.34	58	0.38	28	0.17	6	0.53	267	0.18	37	0.20	26	0.13	2	0.13
Peripheral T-cell lymphoma, NOS	441	0.36	73	0.51	76	0.54	7	0.59	303	0.20	58	0.34	53	0.31	4	0.20
T/NK-cell lymphoid neoplasms, NOS	750	0.61	74	0.55	83	0.56	7	0.44	456	0.31	56	0.33	44	0.23	1	0.05
Lymphoblastic leukemia/lymphoma	2929	2.04	235	1.09	312	1.61	34	0.91	2144	1.47	182	0.81	231	1.18	31	1.01
B-cell lymphoblastic leukemia/lymphoma	1390	0.95	87	0.41	144	0.73	16	0.45	1038	0.72	71	0.32	133	0.68	18	0.56
T-cell lymphoblastic leukemia/lymphoma	463	0.32	66	0.30	58	0.28	4	0.11	192	0.13	35	0.16	28	0.14	2	0.05
Unknown type lymphoblastic leukemia/lymphoma	1076	0.76	82	0.39	110	0.60	14	0.36	914	0.62	76	0.34	70	0.36	11	0.40
Prolymphocytic leukemia	137	0.12	8	0.07	5	0.04	1	0.06	75	0.05	8	0.05	2	0.01	0	0.00
Hodgkin lymphoma	4668	3.29	525	2.83	207	1.16	7	0.39	3887	2.63	457	2.07	183	0.90	14	0.51
Classical Hodgkin lymphoma	4503	3.17	488	2.64	202	1.14	7	0.39	3830	2.60	423	1.91	178	0.87	13	0.45
Nodular sclerosis	2650	1.80	245	1.25	114	0.61	4	0.14	2776	1.89	298	1.31	123	0.56	12	0.40
Mixed cellularity/lymphocyte depleted	1050	0.78	132	0.78	53	0.33	1	0.04	567	0.38	56	0.27	32	0.18	0	0.00
Classical Hodgkin lymphoma, NOS	803	0.59	111	0.61	35	0.20	2	0.21	487	0.33	69	0.32	23	0.13	1	0.05
Nodular lymphocyte predominant Hodgkin lymphoma	165	0.12	37	0.19	5	0.02	0	0.00	57	0.04	34	0.16	5	0.03	1	0.06
Unknown type lymphoid neoplasms	3993	3.27	481	3.18	229	1.70	24	1.44	2844	1.80	262	1.54	153	0.91	9	0.54

AI/AN indicates American Indian or Alaska Native; other abbreviations are explained in Table 1.

*All incidence rates are age adjusted to the 2000 United States population and expressed per 100 000 person-years.

Relative distribution of lymphoid neoplasm subtypes

The burden of disease accounted for by selected subtypes varied by race and age. DLBCL accounted for 21% of all lymphoid neoplasms in whites, and CLL/SLL, plasma cell neoplasms, and follicular lymphoma accounted for 16%, 15%, and 10%, respectively (Figure 3). In contrast, plasma cell neoplasms accounted for 35% of lymphoid neoplasms in blacks, with DLBCL and CLL/SLL accounting for 15% and 13%, respectively; follicular lymphoma accounted for only 5%. The most common lymphoid neoplasm subtypes in Asians were DLBCL (29%) and plasma cell neoplasms (17%), with follicular lymphoma, CLL/SLL, and lymphoblastic leukemia/lymphoma each accounting for 6% to 7% of lymphoid neoplasms.

DLBCL, CLL/SLL, and plasma cell neoplasms each accounted for roughly 20% of lymphoid neoplasms in the elderly (data not shown). In contrast, lymphoblastic leukemia/lymphoma and Hodgkin lymphoma accounted for 50% and 31%, respectively, of lymphoid neoplasms in children (data not shown). The relative distribution of lymphoid neoplasm subtypes for males and females was similar within these race and age groups.

Temporal trends

Incidence trends varied substantially among lymphoid neoplasm subtypes. Overall, total lymphoid neoplasm rates decreased at the rate of 1% per year among males during 1992-2001, from 43.2 to

Table 3. Incidence rate* ratios for lymphoid neoplasms by subtype, race, and sex, 12 SEER registries, 1992-2001

Lymphoid neoplasm subtype	Male-female IRR			White-black IRR		White-Asian IRR	
	White	Black	Asian	Males	Females	Males	Females
Lymphoid neoplasms, total	1.6	1.5	1.5	1.1	1.1	1.7	1.7
B-cell lymphoid neoplasms, total	1.6	1.5	1.5	1.1	1.0	1.7	1.6
DLBCL	1.6	1.8	1.4	1.5	1.6	1.3	1.2
Marginal zone lymphoma	1.0	1.1	1.2	1.2	1.4	0.8	1.0
Follicular lymphoma	1.2	1.6	1.2	2.1	2.8	2.4	2.4
CLL/SLL	1.9	2.0	1.9	1.3	1.4	4.4	4.3
Mantle cell lymphoma	2.5	1.9	1.8	1.9	1.5	2.6	1.9
Burkitt lymphoma/leukemia	3.3	3.8	2.2	1.2	1.4	1.3	0.9
Plasma cell neoplasms	1.6	1.3	1.5	0.5	0.4	1.6	1.5
Multiple myeloma	1.5	1.3	1.4	0.5	0.4	1.6	1.5
Plasma cell leukemia	1.6	1.0	—†	0.5	0.3	—†	1.2
Plasmacytoma	2.2	1.5	3.0	0.8	0.6	1.7	2.3
Hairy cell leukemia	3.8	3.7	5.5	3.0	2.9	3.1	4.5
Lymphoplasmacytic lymphoma	1.5	1.1	3.1	1.2	0.8	1.2	2.3
Waldenström macroglobulinemia	2.2	2.6	2.3	2.2	2.6	1.8	1.8
B-cell lymphoid neoplasms, NOS	1.5	1.9	1.5	1.2	1.5	1.1	1.1
T/NK-cell lymphoid neoplasms, total	1.9	1.5	1.9	0.9	0.7	1.1	1.1
Mycosis fungoides/Sézary syndrome	1.8	1.2	1.8	0.7	0.5	1.4	1.4
Peripheral T-cell lymphoma	1.8	1.7	1.6	0.8	0.7	0.9	0.8
Angioimmunoblastic lymphoma	1.3	2.0	1.7	0.8	1.2	0.5	0.7
Anaplastic large-cell lymphoma	1.9	2.0	1.3	0.9	0.9	1.9	1.3
Peripheral T-cell lymphoma, NOS	1.8	1.5	1.7	0.7	0.6	0.7	0.6
T/NK-cell lymphoid neoplasms, NOS	2.0	1.7	2.4	1.1	0.9	1.1	1.3
Lymphoblastic leukemia/lymphoma	1.4	1.3	1.4	1.9	1.8	1.3	1.3
B-cell lymphoblastic leukemia/lymphoma	1.3	1.3	1.1	2.3	2.3	1.3	1.1
T-cell lymphoblastic leukemia/lymphoma	2.4	1.8	2.0	1.1	0.8	1.1	1.0
Unknown type lymphoblastic leukemia/lymphoma	1.2	1.2	1.6	2.0	1.8	1.3	1.7
Prolymphocytic leukemia	2.6	1.4	3.2	1.7	0.9	3.3	4.1
Hodgkin lymphoma	1.2	1.4	1.3	1.2	1.3	2.8	2.9
Classical Hodgkin lymphoma	1.2	1.4	1.3	1.2	1.4	2.8	3.0
Nodular sclerosis	1.0	1.0	1.1	1.4	1.4	3.0	3.4
Mixed cellularity/lymphocyte depleted	2.0	2.9	1.8	1.0	1.4	2.4	2.1
Classical Hodgkin lymphoma, NOS	1.8	1.9	1.6	1.0	1.0	2.9	2.5
Nodular lymphocyte predominant Hodgkin lymphoma	3.0	1.2	0.9	0.6	0.2	5.0	1.5
Unknown type lymphoid neoplasms	1.8	2.1	1.9	1.0	1.2	1.9	2.0

Italicized IRRs were not statistically significant at $P < .05$ (95% CI included 1.0); 95% CIs available from the author.

IRR indicates incidence rate ratio; other abbreviations are explained in Table 1.

*All incidence rates are age adjusted to the 2000 United States population.

†Calculation of the IRR was precluded by zero cases diagnosed among Asian males.

39.7 cases per 100 000 person-years, but remained unchanged among females (Table 4; Figure 4A).

Among B-cell lymphomas, incidence rates during the 10-year period rose significantly for marginal zone lymphoma, mantle cell lymphoma, and Burkitt lymphoma/leukemia (Figure 4C,F,G) and declined significantly for DLBCL and CLL/SLL (Figure 4B,E). Marginal zone lymphoma increased in all population subgroups from 1992-1996, as this disease subtype became recognized as a distinct entity, and continued to increase 4% to 10% per year during 1996-2001 (data not shown). Incidence of both mantle cell lymphoma and Burkitt lymphoma/leukemia increased approximately 8% per year in the total population, particularly in the elderly. In the total population, DLBCL declined 0.5% per year during 1992-2001. This decline was observed predominantly in men aged 25 to 54, whereas DLBCL increased 1.4% per year in the elderly (data not shown). Rates for immunoblastic lymphoma (ICD-O-3 code 9684), a morphologic variant of DLBCL, declined 17.2% per year (data not shown). During 1992-2001, CLL/SLL decreased 2% to 3% per year for whites and for black men and 9% per year for Asian women, amplifying the excess incidence among whites compared with Asians. Incidence of follicular lymphoma and plasma cell neoplasms did not change significantly overall

(Figure 4D,H), although follicular lymphoma increased 1.8% per year during 1992-2001 among the elderly (data not shown).

Incidence of T/NK-cell neoplasms rose 4% per year, from 2.0 to 2.6 cases per 100 000 person-years in males and from 1.0 to 1.4 cases per 100 000 person-years in females, due especially to increases in peripheral T-cell lymphomas; mycosis fungoides/Sézary syndrome rates remained unchanged (Figure 4J,I).

Overall, Hodgkin lymphoma rates remained stable during 1992-2001. A slight decline in classical Hodgkin lymphoma reflected a 6% per year decline in mixed cellularity/lymphocyte-depleted Hodgkin lymphoma rates (Figure 4N), no change in nodular sclerosis Hodgkin lymphoma rates (Figure 4M), and a 3% per year increase in classical Hodgkin lymphoma—not otherwise specified (NOS) rates. This pattern was substantially different for Asian women, where classical Hodgkin lymphoma increased 7% per year. Rates of nodular lymphocyte predominant Hodgkin lymphoma did not change significantly overall (Figure 4O) but increased 11% per year among children (data not shown).

During 1992-2001, unknown type lymphoid neoplasms decreased 13% per year in males, from 4.7 to 1.2 cases per 100 000 person-years, and 10% per year in females, from 2.5 to 0.9 cases per 100 000 person-years (Figure 4P). Although similar rates of




Figure 2. Incidence of lymphoid neoplasms by subtype, race, sex, and age, 12 SEER registries, 1992-2001. *All incidence rates are age adjusted to the 2000 United States population within age groups. Abbreviations are defined in Table 1.

decline were observed at all ages, the proportion of unknown type lymphoid neoplasms in 2001 remained substantially higher for the elderly than for children (4.4% versus 0.3%, respectively).

Immunophenotype data

During 1992-2001, 39.2% of all lymphoid neoplasm diagnoses were supported by immunophenotype data (data not shown). Although completion of immunophenotype data varied by disease subtype, ranging from less than 1% for plasma cell neoplasms to 76% for marginal zone lymphomas, the concordance between the SEER immunophenotype data and WHO-defined cell lineage was 97% for B-cell and 90% for T/NK-cell lymphoid neoplasms.

Discussion

We observed diverse incidence patterns among more than 114 000 lymphoid neoplasms diagnosed in the United States during 1992-2001. The substantial differences in incidence patterns among the lymphoid neoplasms support clinical, laboratory, and epidemiologic research that increasingly suggests that there is etiologic heterogeneity by disease subtype. This population-based study provides the first comprehensive descriptive analysis of incidence patterns for the entirety of lymphoid neoplasms as defined by the recently introduced WHO classification. Additionally, we present

the first broad description of lymphoid neoplasm incidence patterns and trends for Asian Americans, with detailed evaluation of incidence according to disease subtype and in comparison with incidence among whites and blacks.

The most common lymphoid neoplasm subtypes in Asians were DLBCL and plasma cell neoplasms. We confirm that the substantially lower rates of CLL/SLL in Asia compared with other




Figure 3. Incidence of lymphoid neoplasms by subtype and race, 12 SEER registries, 1992-2001. *All incidence rates are age adjusted to the 2000 United States population. Abbreviations are explained in Table 1.

Table 4. Annual percent changes in lymphoid neoplasm incidence rates* by subtype, race, and sex, 12 SEER registries, 1992-2001

Lymphoid neoplasm subtype	Total†	Men			Women		
		White	Black	Asian	White	Black	Asian
Lymphoid neoplasms, total	-0.50‡	-0.84§	-1.84	-0.33	0.08	0.14	1.39
B-cell lymphoid neoplasms, total	0.51‡	0.28	-1.25	0.86	1.01§	0.43	2.11‡
DLBCL	-0.46§	-0.73§	-2.28	-1.99	0.19	1.27	1.75
Marginal zone lymphoma	21.31§	21.36§	—‖	18.14‡	22.17§	—‖	17.49‡
Follicular lymphoma	0.51	0.10	-1.31	4.48	1.24‡	0.19	-0.05
CLL/SLL	-2.67§	-2.20§	-3.68‡	-0.76	-3.11§	-1.78	-8.99§
Mantle cell lymphoma	8.08§	12.21§	5.74	13.67‡	2.02	—‖	—‖
Burkitt lymphoma/leukemia	8.36§	5.47‡	7.95	17.85§	15.61§	—‖	11.48
Plasma cell neoplasms	-0.73	-0.78	-1.86	-2.06	-0.67	-1.59	2.79
Hairy cell leukemia	-1.84	-2.77‡	—‖	-1.13	2.35	—‖	—‖
Lymphoplasmacytic lymphoma	4.42‡	5.30‡	5.41	5.25	2.86	-5.31	—‖
Waldenström macroglobulinemia	-0.21	1.01	-3.25	-6.51	-1.11	—‖	—‖
B-cell lymphoid neoplasms, NOS	1.64	1.36	3.48	-1.34	2.13	7.53	0.92
T/NK-cell lymphoid neoplasms, total	3.80§	3.45§	1.09	3.73‡	4.32	6.74‡	1.05
Mycosis fungoides/Sézary syndrome	1.11	1.16	-1.73	-5.20	1.32	6.08	-2.09
Peripheral T-cell lymphoma	6.55§	6.21§	0.77	5.09	6.15‡	13.53‡	2.24
T/NK-cell lymphoid neoplasms, NOS	3.26‡	3.01	4.46	7.32	4.52	-0.69	3.05
Lymphoblastic leukemia/lymphoma	0.08	-0.82	-4.03	0.94	2.24	2.17	-1.90
Prolymphocytic leukemia	3.93	0.73	—‖	—‖	3.26	—‖	—‖
Hodgkin lymphoma	-0.49	-0.27	1.18	-0.63	-0.52	-3.12	6.61‡
Classical Hodgkin lymphoma	-0.60‡	-0.41	0.94	-0.41	-0.53	-3.89‡	7.00‡
Nodular sclerosis	0.17	0.66	3.67	0.67	-0.32	-2.65	5.64
Mixed cellularity/lymphocyte depleted	-6.02§	-6.09§	-6.54‡	-8.15	-4.09‡	-11.27	2.76
Classical Hodgkin lymphoma, NOS	3.52‡	3.96‡	6.24	—‖	2.89	-1.05	—‖
Nodular lymphocyte predominant Hodgkin lymphoma	3.20	4.00	5.06	—‖	0.80	4.61	—‖
Unknown type lymphoid neoplasms	-12.41§	-13.86§	-11.00§	-14.28§	-10.78§	-6.82‡	-10.17§

APC indicates annual percent change; other abbreviations are explained in Table 1.

*All incidence rates are age adjusted to the 2000 United States population.

†The total APC is based on the incidence of lymphoid neoplasms among individuals of all races (whites, blacks, Asians, and other or unknown race).

‡ $P < .05$.

§ $P < .01$.

‖Calculation of the APC was precluded by at least one annual rate of zero.

continents persist among Asian Americans, particularly for the elderly.⁵⁴ It is commonly thought that Asians have higher rates of T/NK-cell neoplasms compared with other populations.⁹ We demonstrate that Asians in the United States have a higher *relative* incidence of T/NK-cell neoplasms compared with whites (8% versus 5% of lymphoid neoplasms) but a similar *absolute* incidence of T/NK-cell neoplasms (1.6 versus 1.7 cases per 100 000 person-years). The higher relative incidence of T/NK-cell neoplasms among Asian Americans results from substantially lower incidence compared with whites for B-cell neoplasms (16.3 versus 27.2 cases per 100 000 person-years) and Hodgkin lymphoma (1.0 versus 2.9 cases per 100 000 person-years). Incidence trends among Asian Americans during 1992-2001 were consistent with trends in other populations, with the exception of a 7% per year increase in classical Hodgkin lymphoma for Asian women. Incidence patterns may vary among Asian Americans according to population origin,⁵⁴⁻⁵⁸ but small numbers and the rarity of some disease subtypes precluded analysis of this potential variation. Epidemiologic investigations have demonstrated little difference in lymphoid neoplasm incidence among foreign-born and United States-born Asians,⁵⁵⁻⁵⁸ supporting the role of host susceptibility in lymphoid neoplasm etiology.

Additional research focused on environmental factors and host susceptibility is needed and may benefit from consideration of the lymphoid neoplasms for which rates differ greatly by race or sex. Marked white predominance is observed for hairy cell leukemia and follicular lymphoma, whereas marked black predominance is observed for plasma cell neoplasms. Black predominance also is observed for T/NK-cell neoplasms, most notably for mycosis fungoides/Sézary syndrome. Asians have considerably lower rates

than whites and blacks for CLL/SLL, particularly in the elderly, and Hodgkin lymphoma, particularly in children. Striking male predominance is observed for Burkitt lymphoma/leukemia and hairy cell leukemia, regardless of race. White males also have substantially higher rates than any other sex or race group for mantle cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma. In contrast, rates differed little between males and females for follicular lymphoma, marginal zone lymphoma, and nodular sclerosis Hodgkin lymphoma.

Lymphoid neoplasm incidence in the elderly represents a notable public health burden due to the high rates (170.6 cases per 100 000 person-years) and aging United States population. Further investigations regarding the biology of aging and age-related effects such as immune senescence are particularly important for the subtypes where rates increase most steeply with age, including DLBCL, follicular lymphoma, CLL/SLL, and plasma cell neoplasms. Because the chronic inflammation, DNA damage, and diminished immune surveillance that occur with older age⁵⁹ are also linked with cancer,⁶⁰ we believe they are important avenues of research for these lymphoma subtypes. During 1992-2001, rates of DLBCL and follicular lymphoma in the elderly increased 1.4% and 1.8% per year, respectively. Improved diagnostic specificity during the 1990s^{28,61} did not appear to affect the increasing rates of DLBCL in the elderly. In contrast, rates of CLL/SLL declined 2.1% per year, and rates of plasma cell neoplasms did not change significantly for the elderly. The decline in CLL/SLL is surprising in light of increased recognition of this underdiagnosed disease.^{13,62} This decline suggests that exposures to the still unknown cause(s) of CLL/SLL may have similarly declined.




Figure 4. Trends in incidence of lymphoid neoplasms by subtype, race, and sex, 12 SEER registries, 1992-1995 to 1999-2001. *All incidence rates are age adjusted to the 2000 United States population and presented for 3 fixed time periods (1992-1995, 1996-1998, 1999-2001). †Presentation of trends for certain populations was precluded by at least one annual rate of zero. Abbreviations are defined in Table 1.

Some of the greatest variation in incidence among lymphoid neoplasms is seen in children. Incidence of lymphoblastic leukemia/lymphoma is higher in children than in any other age group; in contrast, incidence for several subtypes, including follicular lymphoma, CLL/SLL, and plasma cell neoplasms, is virtually nonexistent

in children. During 1992-2001, lymphoblastic leukemia/lymphoma accounted for 50% and Hodgkin lymphoma accounted for 31% of lymphoid neoplasms in children (2.9 cases and 1.8 cases per 100 000 person-years, respectively). Substantial international variation for both absolute rates and relative frequencies of

childhood lymphoid neoplasms has been demonstrated, providing important etiologic clues.⁶³ Incidence of lymphoblastic leukemia/lymphoma is higher in areas with higher socioeconomic development, with rates among United States whites 4 times higher than rates in sub-Saharan Africa.⁶³ In contrast, Burkitt lymphoma/leukemia is the most common childhood cancer in tropical Africa, where incidence is related to EBV and malaria.⁶⁴ We confirm the continued stability of lymphoblastic leukemia/lymphoma and Burkitt lymphoma/leukemia rates in United States children⁶⁵ and a continuation of the decades-long decline in classical Hodgkin lymphoma, particularly in the mixed cellularity/lymphocyte-depleted subtype, though the causes of this decline remain unknown.^{33,34,65} During 1992-2001, lymphoid neoplasms accounted for approximately one third of all cancers diagnosed in children in the United States⁴²; thus, understanding the effects of perinatal and early life exposures in the etiology of these neoplasms may be important.

Although the HIV status is not known for cancer cases reported to SEER registries, the observed excess incidence among white and black men aged 25 to 54 compared with other race, sex, and age groups for DLBCL (including immunoblastic lymphoma), Burkitt lymphoma, and mixed cellularity/lymphocyte depleted Hodgkin lymphoma is consistent with previous reports identifying these subtypes as AIDS-related lymphomas.^{15,29,30,37,66-71} The observed excess incidence in this population for unknown type lymphoid neoplasms also suggests that AIDS cases are disproportionately less likely to be assigned a specific WHO subtype. Declining incidence of DLBCL and mixed cellularity/lymphocyte depleted Hodgkin lymphoma in this population subgroup, particularly during 1995-2001, may reflect the impact of highly active antiretroviral therapy introduced in the mid 1990s, which increases immune function in patients with AIDS and reduces the risk of AIDS-related lymphomas.^{67-69,71} Additional analyses that can explicitly identify HIV-positive individuals are better suited to examining the incidence patterns for AIDS-related lymphomas.

The main limitation of this analysis is a lack of central pathology review for all cases. Nevertheless, although diagnostic practices have changed considerably during the past 15 years, agreement among hematopathologists is much improved in the REAL and WHO classifications compared with earlier classifications.^{29,61} Diagnostic concordance among expert hematologists⁶¹ and between registry coding and expert pathologic review⁷² has been estimated to be more than 85% for most REAL and WHO lymphoid neoplasm subtypes. Only for Burkitt lymphoma/leukemia was substantially lower agreement (about 50%) reported.^{61,72} The use of cases classified according to ICD-O-2, prior to the introduction of the WHO classification, is another limitation of this analysis. For cases originally classified in ICD-O-2, a comparison of the ICD-O-3 code assigned by the conversion algorithm⁴⁰ and the ICD-O-3 code that would have been assigned by a SEER reviewer suggests that agreement is generally high for the major subtypes (follicular lymphoma [88%], DLBCL [87%], CLL/SLL [80%], peripheral T-cell lymphoma [74%], and mycosis fungoides/Sézary syndrome [73%]).⁷³ Additional limitations of this analysis include the variation between hospitals in the quality and level of expert hematopathologic review, potential errors in the coding of lymphoid neoplasms, missing or incomplete data in the registry, and the potential underestimate of incidence rates for more recent years due to reporting delays.⁴¹ To minimize these potential errors, SEER registries are rigorously evaluated for data quality and completeness, with case ascertainment of 98% or greater in all

registries, and SEER reviewers undergo extensive training for general cancer registration and for specific cancer sites.

Changes in diagnostic practice likely are responsible for the increasing rates of marginal zone and mantle cell lymphomas and decreasing rates of unknown type lymphoid neoplasms. Increased incidence of marginal zone lymphoma during 1992-1995 reflects the implementation of ICD-O-2 codes specific for marginal zone lymphoma by SEER registries in 1995.⁴⁰ It is plausible that the 4% to 10% increases per year for marginal zone lymphoma during 1996-2001 reflect improving recognition by pathologists, although true changes in incidence resulting from changes in risk factor prevalence cannot be ruled out. Risk of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), the most common type of marginal zone lymphoma, is related to inflammation resulting from autoimmune diseases or gastritis associated with infections such as *Helicobacter pylori*.^{28,74} The incidence of autoimmune conditions may be increasing slightly in the United States,⁷⁵ whereas the incidence of *H pylori* infections has decreased in developed countries in more recent birth cohorts.⁷⁶ Thus, the impact of changes in risk factor prevalence on trends in marginal zone lymphoma is unclear. Nevertheless, the similar seroprevalence of *H pylori* between men and women in the United States⁷⁷ and the predominance of autoimmune diseases among women⁷⁵ may explain why the male-to-female IRR for marginal zone lymphoma is lower than that of any other B-cell lymphoid neoplasm. Increased incidence of mantle cell lymphoma during 1992-2001 likely reflects improved diagnosis of this subtype, particularly with the introduction of immunohistochemical staining for cyclin D1, which is overexpressed in virtually all mantle cell lymphomas.⁷⁸⁻⁸⁰ During 1992-2001, rates for unknown type lymphoid neoplasms in the total population decreased 12% per year; a similar rate of decline was observed in all race, sex, and age groups. This decrease is likely due to increased diagnostic specificity resulting from the incorporation of entities described by the REAL and WHO classifications and utilization of cytogenetic and immunophenotypic data. The decline in unknown type lymphoid neoplasms could therefore contribute artifactually to the increase we observed for some subtypes and attenuate the estimated decline we observed for other subtypes, particularly for AIDS-related subtypes. Increased efforts to classify cases are necessary to resolve this uncertainty; nevertheless, unknown type lymphoid neoplasms still made up more than 3% of lymphoid neoplasms in 2001.

Despite our use of the recently introduced WHO classification for our analysis, several important categories, such as DLBCL, remain heterogeneous with respect to molecular characteristics and gene-expression profiles.⁸¹⁻⁸⁸ Future research is needed to understand the etiologic relevance of this heterogeneity and its consequences for lymphoid neoplasm classification.

We conclude that the striking differences in incidence patterns by histologic subtype strongly suggest that there is etiologic heterogeneity among lymphoid neoplasms and support the pursuit of epidemiologic analysis by subtype. The established specificity of certain infections^{74,89-90} and increasing evidence suggesting that certain risk factors⁹¹ and host susceptibility⁹² may be related to specific subtypes further support this conclusion, although it remains plausible that some risk factors are related to multiple subtypes or all lymphomas.⁷⁰ Research within large consortium efforts such as InterLymph, the International Lymphoma Epidemiology Consortium,^{93,94} will likely contribute to identifying the elusive etiologic causes of lymphoid neoplasms.

References

- Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. *CA Cancer J Clin*. 2005;55:10-30.
- Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. *Oncogene*. 2004;23:6524-6534.
- Cartwright RA, Watkins G. Epidemiology of Hodgkin's disease: a review. *Hematol Oncol*. 2004;22:11-26.
- Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. *Cancer Cell*. 2004;6:439-444.
- Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. *N Engl J Med*. 2005;352:804-815.
- Linnet MS, Devesa SS, Morgan GJ. New perspectives on the epidemiology of hematologic malignancies and related disorders. In: Shields PG, ed. *Cancer Risk Assessment Methodologies, Biomarkers, and Epidemiology*. New York, NY: Marcel Dekker; 2005:647-691.
- Hartge P, Bracci PM, Wang SS, Devesa SS, Holly EA. Non-Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JF Jr, eds. *Cancer Epidemiology and Prevention*. 3rd ed. Oxford, England: Oxford Press; 2005.
- Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. *Lancet Oncol*. 2004;5:341-353.
- Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. *Ann Hematol*. 2005;84:1-12.
- Dorn H, Cutler S. Morbidity from cancer in the United States. Public Health Monograph No. 56. Washington DC: US Government Printing Office; 1958.
- Zheng T, Mayne S, Boyle P, Holford T, Liu W, Flannery J. Epidemiology of non-Hodgkin's lymphomas in Connecticut, 1935-1988. *Cancer*. 1992;70:840-849.
- Hartge P, Devesa SS, Fraumeni JF Jr. Hodgkin's and non-Hodgkin's lymphomas. *Cancer Surv*. 1994;19-20:423-453.
- Cartwright RA. Time trends in incidence of haematological malignancies and related conditions. *Br J Haematol*. 1999;106:281-295.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov/publicdata) SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2003 Sub (1973-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. Accessed June 24, 2004.
- Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. *J Natl Cancer Inst*. 2002;94:1204-1210.
- Hartge P, Devesa SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. *Cancer Res*. 1992;52(19 suppl):5566s-5569s.
- Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. *Cancer Res*. 1992;52(19 suppl):5432s-5440s.
- Liu S, Semenciw R, Mao Y. Increasing incidence of non-Hodgkin's lymphoma in Canada, 1970-1996: age-period-cohort analysis. *Hematol Oncol*. 2003;21:57-66.
- Gail MH, Pluda JM, Rabkin CS, et al. Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. *J Natl Cancer Inst*. 1991;83:695-701.
- Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. *Cancer*. 2002;94:2015-2023.
- Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. *J Natl Cancer Inst*. 2001;93:824-842.
- Hardell L, Eriksson M. Is the decline of the increasing incidence of non-Hodgkin lymphoma in Sweden and other countries a result of cancer preventive measures? *Environ Health Perspect*. 2003;111:1704-1706.
- Aisenberg AC. Historical review of lymphomas. *Br J Haematol*. 2000;109:466-476.
- Harris N, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood*. 1994;84:1361-1392.
- Cogliatti SB, Schmid U. Who is WHO and what was REAL? *Swiss Med Wkly*. 2002;132:607-617.
- National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. *Cancer*. 1982;49:2112-2135.
- Herrinton LJ. Epidemiology of the Revised European-American Lymphoma classification subtypes. *Epidemiol Rev*. 1998;20:187-203.
- Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC Press; 2001.
- Groves F, Linnet M, Travis L, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. *J Natl Cancer Inst*. 2000;92:1240-1251.
- Coté T, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. *Int J Cancer*. 1997;73:645-650.
- Boerma EG, van Imhoff GW, Appel IM, Veeger NJGM, Kluin P, Kluin-Nelemans JC. Gender and age-related differences in Burkitt lymphoma - epidemiological and clinical data from The Netherlands. *Eur J Cancer*. 2004;40:2781-2787.
- Cartwright R, Brincker H, Carli PM, et al. The rise in incidence of lymphomas in Europe 1985-1992. *Eur J Cancer*. 1999;35:627-633.
- Chen YT, Zheng T, Chou M-C, Boyle P, Holford TR. The increase of Hodgkin's disease incidence among young adults. Experience in Connecticut, 1935-1992. *Cancer*. 1997;79:2209-2218.
- Glaser SL, Swartz W. Time trends in Hodgkin's disease incidence. The role of diagnostic accuracy. *Cancer*. 1990;66:2196-2204.
- Broccia G, Cocco P, Casula P. Incidence of non-Hodgkin's lymphoma and Hodgkin's disease in Sardinia, Italy: 1974-1993. *Haematologica*. 2001;86:58-63.
- Varterasian ML, Graff JJ, Severson RK, Weiss L, Al-Katib AM, Kalemkerian GP. Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database. *Cancer Invest*. 2000;18:303-308.
- Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphoma. *Cancer*. 1995;75(1 suppl):370-380.
- Gurney KA, Cartwright RA. Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. *Hematol J*. 2002;3:95-104.
- Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. *Int J Cancer*. 1997;72:923-930.
- Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, second edition to International Classification of Diseases for Oncology, third edition. Cancer Statistics Branch, DCCPS, SEER Program, National Cancer Institute; 2001. Available at: <http://seer.cancer.gov/tools/conversion/ICD02-3manual.pdf>. Accessed July 19, 2004.
- Ries LAG, Eisner MP, Kosary CL, eds. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2001/. Accessed July 19, 2004.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov/publicdata) SEER*Stat Database: Incidence - SEER 11 Regs + AK Public-Use, Nov 2003 Sub for Expanded Races (1992-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. Accessed June 24, 2004.
- Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. *Cancer Epidemiol Biomarkers Prev*. 1999;8:1117-1121.
- Percy C, Van Holten V, Muir C, eds. *International Classification of Diseases for Oncology*. 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
- Fritz A, Percy C, Jack A, et al, eds. *International Classification of Diseases for Oncology*. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
- Stansfeld A, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. *The Lancet* 1988;1(8580):292-293.
- Bennett JM, Catovsky D, Daniel M, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *Br J Haematol*. 1976;33:451-458.
- Bennett JM, Catovsky D, Daniel M, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. *J Clin Pathol*. 1989;42:567-584.
- Linnet MS, Devesa SS. Epidemiology of leukemia: overview and patterns of occurrence. In: Henderson ES, Lister TA, Greaves MF, eds. *Leukemia*. 7th ed. Philadelphia, PA: Saunders; 2002:131-151.
- Roman E, Doyle P, Maconochie N, Davies G, Smith PG, Beral V. Cancer in children of nuclear industry employees: report on children aged under 25 years from nuclear industry family study. *BMJ*. 1999;318:1443-1450.
- Surveillance Research Program, National Cancer Institute SEER*Stat software, version 5.2.2. Available at: www.seer.cancer.gov/seerstat/software. Accessed June 24, 2004.
- Miettinen O, Nurminen M. Comparative analysis of two rates. *Stat Med*. 1985;4:213-226.
- Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. *Am J Epidemiol*. 1995;141:300-304.
- Finch SC, Linnet MS. Chronic leukemias. *Baillieres Clin Haematol*. 1992;5:27-56.
- Ducore JM. Cancer occurrence in Southeast Asian children in California. *J Pediatr Hematol Oncol*. 2004;26:613-618.
- Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. *Br J Haematol*. 2005;128:792-796.
- Herrinton LJ, Goldoft M, Schwartz SM, Weiss NS. The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the

- United States and their descendants. *Cancer Causes Control*. 1996;7:224-230.
58. Pan JWY, Cook LS, Schwartz SM, Weiss NS. Incidence of leukemia in Asian migrants to the United States and their descendants. *Cancer Causes Control*. 2002;13:791-795.
 59. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype. *Autoimmun Rev*. 2004;3:401-406.
 60. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420:860-867.
 61. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*. 1997;89:3909-3918.
 62. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. *Cancer*. 2001;92:1325-1330.
 63. Stiller CA. Epidemiology and genetics of childhood cancer. *Oncogene*. 2004;23:6429-6444.
 64. van den Bosch CA. Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? *Lancet Oncol*. 2004;5:738-746.
 65. Linet MS, Ries LAG, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. *J Natl Cancer Inst*. 1999;91:1051-1058.
 66. Biggar RJ. AIDS-related cancers in the era of highly active antiretroviral therapy. *Oncology*. 2001;15:439-449.
 67. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. *Blood*. 2001;98:3406-3412.
 68. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. *J Natl Cancer Inst*. 2000;92:1823-1830.
 69. Cheung TW. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. *Cancer Invest*. 2004;22:787-798.
 70. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. *Lancet*. 1998;351:1833-1839.
 71. Grulich AE, Li Y, McDonald A, Correll P, Law M, Kaldor J. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. *AIDS*. 2001;15:629-633.
 72. Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. *Cancer Epidemiol Biomarkers Prev*. 2004;13:138-143.
 73. Clarke CA, Undurraga DM, Morton LM, Harasty PJ, Holly EA, Glaser SL. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. *Cancer Epidemiol Biomarkers Prev*. In press.
 74. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. *Blood*. 2000;96:410-419.
 75. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. *Clin Immunol Immunopathol*. 1997;84:223-243.
 76. Roosendaal R, Kuipers EJ, Buitener J, et al. *Helicobacter pylori* and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. *Am J Gastroenterol*. 1997;92:1480-1482.
 77. McQuillan GM, Kruszon-Moran D, Kottiri BJ, Curtin LR, Lucas JW, Kingdon RS. Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. *Am J Public Health*. 2004;94:1952-1958.
 78. Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. *Curr Opin Hematol*. 2004;11:411-418.
 79. Weisenburger DD, Armitage JO. Mantle cell lymphoma—an entity comes of age. *Blood*. 1996;87:4483-4494.
 80. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. *Blood*. 2000;95:2253-2261.
 81. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*. 2004;103:275-282.
 82. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N Engl J Med*. 2004;351:2159-2169.
 83. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *N Engl J Med*. 2002;346:1937-1947.
 84. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*. 2000;403:503-511.
 85. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood*. 2005;105:1851-1861.
 86. Iqbal J, Sanger W, Horsman D, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. *Am J Pathol*. 2004;165:159-166.
 87. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. *N Engl J Med*. 2004;350:1828-1837.
 88. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2003;44(suppl 3):S41-S47.
 89. Chadburn A. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. *Am J Surg Pathol*. 2004;28:1401-1416.
 90. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. *Oncogene*. 2003;22:5131-5140.
 91. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin lymphoma: a case-control study [abstract]. *Proc Am Assoc Cancer Res*. 2005;46:4382.
 92. Wang SS, Hartge P, Cerhan JR, et al. Non-Hodgkin lymphoma and immune gene polymorphisms: inflammatory cytokines, Th1/Th2 cytokines, innate immunity, chemokines, adhesion molecules, and interferons [abstract]. *Proc Am Assoc Cancer Res*. 2005;46:4383.
 93. Boffetta P, Linet MS, Armstrong BK. The InterLymph collaboration: a consortium of molecular epidemiological studies of non-Hodgkin's lymphoma [abstract]. *Proc Am Assoc Cancer Res*. 2003;44(2nd ed):1579.
 94. Morton LM, Hartge P, Holford TR, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the InterLymph consortium. *Cancer Epidemiol Biomarkers Prev*. 2005;14:925-933.